Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.
Calidi Biotherapeutics, Inc. (CLDI) is a clinical-stage immuno-oncology company at the forefront of advancing cancer treatment methodologies. The company specializes in the development and commercialization of innovative, stem cell-based platforms designed to enhance the delivery and effectiveness of oncolytic viruses in cancer therapy.
Calidi’s core business involves leveraging its proprietary Neuro-Cells™ and SuperNova™ technology platforms. These platforms are engineered to deliver oncolytic viruses directly to tumor sites, ensuring targeted and potent cancer cell destruction while minimizing damage to surrounding healthy tissues.
Among the company's recent achievements, Calidi has successfully completed several preclinical studies demonstrating the efficacy and safety of its therapeutic candidates. Currently, Calidi is undergoing multiple Phase I/II clinical trials to further validate these findings and advance towards regulatory approvals.
Financially, Calidi Biotherapeutics has secured significant investment and formed strategic partnerships with key players in the biotechnology and pharmaceutical industries. These collaborations aim to accelerate the development timelines and expand the potential applications of their oncolytic virus therapies.
Calidi’s commitment to innovation and excellence is evident in its robust pipeline of products and ongoing research initiatives. The company continues to explore new avenues for the application of its technologies, with the ultimate goal of offering effective and life-saving treatments for cancer patients worldwide.
For the latest updates and news about Calidi Biotherapeutics, including their ongoing clinical trials and partnerships, visit their official news section.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm, reported its Q1 2024 financial results and business developments. Key highlights include three upcoming posters at the 2024 ASCO Annual Meeting, featuring an update from the ongoing Phase 1 trial of CLD-101 for recurrent high-grade glioma.
Calidi also presented new data on its immunotherapies at the AACR Annual Meeting and unveiled the RTNova systemic delivery platform targeting multiple tumor types. The company completed a $6.1 million public offering, strengthening its balance sheet amid ongoing capital-raising efforts and cost-cutting measures to advance its pipeline.
Financially, Calidi reported a net loss of $7.2 million ($0.20 per share) for Q1 2024, a slight increase from $6.5 million ($0.75 per share) in Q1 2023. R&D expenses increased marginally to $2.7 million, while G&A expenses grew to $4.0 million from $2.8 million. The company ended Q1 2024 with $1.2 million in cash and $0.2 million in restricted cash.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) announced the acceptance of three abstracts for presentation at the 2024 ASCO Annual Meeting. The abstracts focus on their innovative programs for the treatment of high-grade glioma and solid tumors. Calidi will present updates on their CLD-101, RTNova, and CLD-201 programs, showcasing their cutting-edge therapeutic candidates.
FAQ
What is the current stock price of Calidi Biotherapeutics (CLDI)?
What is the market cap of Calidi Biotherapeutics (CLDI)?
What is Calidi Biotherapeutics, Inc.?
What technologies does Calidi Biotherapeutics use?
What is the current focus of Calidi Biotherapeutics?
Has Calidi Biotherapeutics achieved any recent milestones?
Who are Calidi Biotherapeutics' industry partners?
What is the goal of Calidi’s stem cell-based platforms?
What are oncolytic viruses?
Where can I find the latest news about Calidi Biotherapeutics?
What are the main products of Calidi Biotherapeutics?
What is the long-term vision of Calidi Biotherapeutics?
